



Medical Physics Seminar




Monday, November 14, 2016

1345 HSLC —4:00 PM



Melissa C. Skala, Ph.D.
Investigator, Morgridge Institute for Research
Associate Professor of Biomedical Engineering,
University of Wisconsin - Madison

Optical metabolic imaging of cellular heterogeneity in cancer



Abnormal cellular metabolism is a hallmark of many diseases, yet there is an absence of quantitative methods to dynamically image metabolism with cellular-level resolution. Optical metabolic imaging (OMI) quantifies the fluorescence intensities and lifetimes of the metabolic co-enzymes NADH and FAD using two-photon microscopy. OMI is a label-free, high-resolution, quantitative tool for monitoring cellular metabolism within intact samples. *In vivo* OMI is sensitive to heterogeneous changes in cellular metabolism induced by clinically relevant anti-cancer therapies in mouse models of cancer. The ability to monitor these treatment-resistant sub-populations of cells *in vivo* is important for identifying and eliminating the particularly lethal cells that cause tumor recurrence and metastases. We have further developed a “tumor-in-a-dish” organoid platform to rapidly test multi-drug response using OMI. This platform has been validated in mouse models of breast and pancreas cancer, and feasibility has been tested in human tumors with chemotherapies, targeted therapies, and experimental drugs. Importantly, the cellular-level assessment of OMI allows for sub-populations of cells with varying response to drug treatment to be tracked over time, in order to achieve therapeutic effect in all cell populations. This attractive suite of metabolic imaging tools has significant implications for rapid cellular-level assessment of metabolic response to drug treatment (1) *in vivo*, (2) in high-throughput drug efficacy studies, and (3) as a clinical tool to plan individualized treatment regimens. Therefore, these technologies could greatly accelerate cures for cancer patients.

1345 HEALTH SCIENCES LEARNING CENTER (HSLC) - 4:00 - 5:00 P.M.